Financial Comparison: Coeptis Therapeutics (NASDAQ:ZSQR) vs. Next Technology (NASDAQ:NXTT)

Next Technology (NASDAQ:NXTT) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Profitability

This table compares Next Technology and Coeptis Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Next Technology	-2,355.97%	-60.08%	-53.71%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Next Technology and Coeptis Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Next Technology	1	0	0	0	1.00
Coeptis Therapeutics	1	0	0	0	1.00

Insider and Institutional Ownership

2.7% of Next Technology shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 52.2% of Next Technology shares are held by insiders. Comparatively, 24.2% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Next Technology has a beta of 5.98, suggesting that its stock price is 498% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.29, suggesting that its stock price is 129% less volatile than the S&P 500.

Earnings and Valuation

This table compares Next Technology and Coeptis Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Next Technology	$11.61 million	0.64	$143.16 million	($12,900.00)	-0.00
Coeptis Therapeutics	$1.36 million	214.34	-$11.92 million	($1.63)	-3.37

Next Technology has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Next Technology, indicating that it is currently the more affordable of the two stocks.

Summary

Coeptis Therapeutics beats Next Technology on 6 of the 11 factors compared between the two stocks.

About Next Technology

Next Technology Holding Inc. provides technical services and solutions through its social e-commerce platform primarily in Mainland China. It offers YCloud, a micro-business cloud intelligent internationalization system that conducts multi-channel data analysis through the learning of big data and social recommendation relationships, as well as provides users with AI fission and management systems, and supply chain systems. The company’s YCloud system also provides micro-business owners with various payment methods, such as Alipay, WeChat, and UnionPay. In addition, it offers chatGPT technical services; and technical system support, software development, and services. The company serves individual and corporate users in the micro business industry. It also has operations in Hong Kong and Singapore. The company was formerly known as WeTrade Group, Inc. and changed its name to Next Technology Holding Inc in April 2024. Next Technology Holding Inc. was incorporated in 2019 and is headquartered in Beijing, the People Republic of China.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.